{"id":"W2294562171","doi":"10.1200/jco.2013.31.15_suppl.tps7131","title":"A phase III, randomized, controlled study evaluating the efficacy and safety of idelalisib (GS-1101) in combination with ofatumumab for previously treated chronic lymphocytic leukemia (CLL).","year":2013,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":20,"is_retracted":false,"has_abstract":true,"ca_institutions":"Baker Hughes (Canada)","funders":"","keywords":"Idelalisib; Ofatumumab; Medicine; Internal medicine; Chronic lymphocytic leukemia; Bendamustine; Alemtuzumab; Fludarabine; Oncology; Ibrutinib; CD20; IGHV@; Gastroenterology; Leukemia; Immunology; Chemotherapy; Lymphoma; Cyclophosphamide","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002190124,0.001672987,0.00265875,0.0004354126,0.0005229635,0.00113815,0.0009129542,0.001692301,0.006711676],"category_scores_gemma":[0.001630668,0.0008697473,0.001548451,0.0004903114,0.001254038,0.00116844,0.0004289357,0.00328827,0.001257537],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001104603,"about_ca_system_score_gemma":0.001834434,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001407405,"about_ca_topic_score_gemma":0.003551768,"domain_scores_codex":[0.9993539,0.0003326408,0.00003290055,0.0001167788,0.00005148198,0.000112331],"domain_scores_gemma":[0.9990076,0.0002023172,0.0002437388,0.00006094429,0.00006074671,0.0004245731],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9665058,0.01269881,0.00127166,0.0004440404,0.0009199279,0.00006321306,0.00004771277,0.0002842233,0.003583505,0.00008761295,0.0009860102,0.01310761],"study_design_scores_gemma":[0.9331558,0.06399722,0.001550535,0.00001512605,0.0002757305,0.00003565358,0.00001341605,0.0002291423,0.0001916421,0.00005728679,0.0004707548,0.000007629683],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9829198,0.00341047,0.0008023056,0.0008478301,0.0005731491,0.007406053,0.001555229,0.0001430037,0.00234228],"genre_scores_gemma":[0.9803931,0.002784827,0.001997339,0.001676809,0.0004588848,0.008141672,0.001638042,0.00002759435,0.00288173],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.006711676,"threshold_uncertainty_score":0.02245277,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.08759778079866323,"score_gpt":0.4827884970728645,"score_spread":0.3951907162742012,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}